

Type of Cancer	Open Immunotherapy Clinical Trials	You may be eligible if:	Location open
Breast	Merck MK-3475-355 Keynote 355 Breast Cancer A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (mTNBC)	<ul style="list-style-type: none"> • 18 years or older • Must not have had previous chemotherapy treatment for recurrent breast cancer or metastatic disease that has not been treated with chemotherapy • Diagnosis of triple negative breast cancer • Disease that can be measured by CT scan • Otherwise Healthy 	Sioux Falls, SD Fargo, SD
	NantBioScience CMS-005 Breast Cancer Phase I Study of Ad5 [E1-, E2b-]-HER2/neu Vaccine (ETBX-021) in Subjects with Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer	<ul style="list-style-type: none"> • 18 years and older • Diagnosis of unresectable locally advanced or metastatic breast cancer that expresses HER2 (IHC 1+ and 2+) • No concurrent HER2 directed therapy • Otherwise Healthy 	Sioux Falls, SD
Colorectal	Merck MK-3475-177 Keynote 177 Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma	<ul style="list-style-type: none"> • 18 years or older • Diagnosed with MMR deficient or microsatellite instability high stage IV colorectal carcinoma • Must not have received prior systemic therapy for stage IV CRC • Otherwise healthy 	Sioux Falls, SD
Gastrointestinal	CheckMate 358 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors	<ul style="list-style-type: none"> • 18 years or older • Diagnosis of EBV-Positive Gastric or Gastro-Esophageal Junction Carcinoma • Have progressive metastatic/recurrent and measurable disease • Otherwise Healthy 	Sioux Falls, SD
Genitourinary	Merck MK-3475-426 Keynote 426 A Phase III randomized, open-label, clinical trial to study the efficacy and safety of pembrolizumab (MK3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for locally advanced/metastatic renal cell carcinoma (mRCC)	<ul style="list-style-type: none"> • 18 years and older • Diagnosis of renal cell carcinoma with clear cell component without sarcomatoid features • Locally advanced/metastatic disease or recurrent disease • No prior systemic therapy for advanced RCC • Otherwise healthy 	Sioux Falls, SD
	Merck MK-3475-199 Keynote 199 Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)	<ul style="list-style-type: none"> • 18 years or older • Prostate cancer progression within 6 months prior to screening • May have had prior chemotherapy or showing signs of failure on enzalutamide therapy • Otherwise healthy 	Sioux Falls, SD Fargo, ND Bismarck, ND
Gynecologic	CheckMate 358 (Cervical) Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors	<ul style="list-style-type: none"> • 18 years or older • Diagnosis of Stage II to IVa disease • Squamous cell carcinoma • Are eligible for planned surgery or chemotherapy/radiation therapy • Otherwise Healthy 	Sioux Falls, SD
Head and Neck	CheckMate 358 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors	<ul style="list-style-type: none"> • 18 years or older • Diagnosis of HNSCC or nasopharyngeal carcinoma • Are eligible for surgical resection or have progressive metastatic/recurrent disease • Otherwise Healthy 	Sioux Falls, SD
	SH MISP203 Phase IB study of Pembrolizumab in combination with chemo radiotherapy (CRT) for locally-advanced squamous cell carcinoma of the head and neck (SCCHN)	<ul style="list-style-type: none"> • 18 years or older • Diagnosis of HNSCC • Are eligible for curative intent treatment • Otherwise healthy 	Sioux Falls, SD Fargo, ND Bismarck, ND
	Incyte BMS INCB24360-204 Advanced Tumors A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers	<ul style="list-style-type: none"> • 18 years or older • Have confirmed metastatic or recurrent squamous cell carcinoma of head and neck • No more than 2 prior systemic regimens • Must have measurable disease • Otherwise Healthy 	Sioux Falls, SD Fargo, ND

Type of Cancer	Open Immunotherapy Clinical Trials	You may be eligible if:	Location open
Lung	CTSU S1400 (MAP) Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer	<ul style="list-style-type: none"> • 18 years or older • Diagnosis of Squamous Cell Lung Carcinoma • Disease that can be measured on a CT scan • Received at least 1 line of platinum-based chemotherapy • Otherwise Healthy 	Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN
	Alliance A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)	<ul style="list-style-type: none"> • 18 years or older • Diagnosis of stage IB-IIIa NSCLC • Must have complete resection • Must have tissue available for EGFR/ALK testing • Otherwise Healthy 	Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN
	Incyte BMS INCB24360-204 Advanced Tumors A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers	<ul style="list-style-type: none"> • 18 years or older • Stage IIIB, IV or recurrent unresectable NSCLC • Must have received 1 prior systemic regimen • Must have measurable disease • Otherwise Healthy 	Sioux Falls, SD Fargo, ND
	BMS CA209-451 Checkmate 451 A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance in Subjects with Extensive-Stage Disease Small-Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy (CA209-451 / NCT02538666)	<ul style="list-style-type: none"> • 18 years or older • Diagnosis of extensive stage SCLC • Must have received 4 cycles of first line platinum-based chemotherapy and had a response to therapy • Must have tissue available for review • Must be enrolled within 9 weeks of the last dose of platinum-based first line chemotherapy • Otherwise healthy 	Sioux Falls, SD Fargo, ND
	ECOG-ACRIN EA5142 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers	<ul style="list-style-type: none"> • 18 years or older • Complete surgical resection of Stage IB, II or IIA NSCLC • Non-squamous tumors must be EGFR and ALK wild type and must have PD-L1 status tested • Must have recovered from surgery and chemotherapy • Otherwise healthy 	Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN
	BMS CA209-370 Checkmate 370 A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies (CA209370)	<ul style="list-style-type: none"> • 18 years or older • Locally advanced or Stage 4 NSCLC • EGFR mutation positive • ALK negative/wild type or indeterminate • Measurable disease • Must have tissue available for review • Otherwise healthy 	Sioux Falls, SD
Melanoma	ECOG-ACRIN EA6134 A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma	<ul style="list-style-type: none"> • 18 years or older • Diagnosis of unresectable Stage III or IV Melanoma • Disease that can be measured by CT scan • Must have BRAFV600 mutation • Otherwise Healthy 	Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN
	ECOG-ACRIN EA6141 Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma	<ul style="list-style-type: none"> • 18 years or older • Diagnosis of unresectable Stage III or IV Melanoma • Disease that can be measured by CT scan • Must have known BRAF mutational status (Wild-type or mutated) • Otherwise Healthy 	Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN
	Incyte BMS INCB24360-204 Advanced Tumors A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers	<ul style="list-style-type: none"> • 18 years or older • Diagnosis of stage IV melanoma • BRAFV600E mutation status • May be treatment naive or had 1 prior treatment • Must have measurable disease • Otherwise Healthy 	Sioux Falls, SD Fargo, ND
Merkel Cell Skin Cancer	CheckMate 358 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors	<ul style="list-style-type: none"> • 18 years or older • Eligible for neo-adjuvant treatment • Otherwise Healthy 	Sioux Falls, SD

Type of Cancer	Open Immunotherapy Clinical Trials	You may be eligible if:	Location open
Renal Cell Carcinoma	EA8143 A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma undergoing Nephrectomy (PROSPER RCC)	<ul style="list-style-type: none"> • 18 years or older • Newly diagnosed renal cell cancer • Radical or partial nephrectomy is planned 	Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN
Sarcoma	A091401 Randomized Phase II Study of Nivolumab with or without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma	<ul style="list-style-type: none"> • 18 years of age • Histologically confirmed LPS (liposarcoma), UPS/ MFH (undifferentiated pleomorphic sarcoma/ Malignant fibrous histiocytoma) or GIST (gastrointestinal stromal tumor) • ≥ 1 prior systemic therapy for sarcoma • Measurable disease 	Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN
Squamous Cell Carcinoma	Merck MK-3475-629-00 A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)	<ul style="list-style-type: none"> • 18 years or older • Diagnosis of Cutaneous Squamous Cell Carcinoma • Measurable metastatic and/or unresectable disease that is not curable by surgery, radiation, or systemic therapy • Otherwise healthy 	Sioux Falls, SD
Targeted Studies	ASCO TAPUR The Targeted Agent and Profiling Utilization Registry (TAPUR) Study	<ul style="list-style-type: none"> • 18 years or older • Locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma • Either no longer benefitting from treatment or no standard treatment available • Must have a genomic test or IHC test of tumor available from certified lab • Genomic profile matches FDA anti-cancer therapies in the study • Measurable disease • Otherwise Healthy 	Sioux Falls, SD Fargo, ND Bismarck, ND
	ECOG-ACRIN EAY131 NCI MATCH Molecular Analysis for therapy choice (MATCH)	<ul style="list-style-type: none"> • 18 years or older • Solid tumors, lymphoma or multiple myeloma • Either no longer benefitting from treatment or no standard treatment available • Must have measurable disease • Must have tissue available for review • Must have a genomic test or IHC test of tumor available from certified lab • Genomic profile matches FDA anti-cancer therapy in the study • Otherwise healthy 	Sioux Falls, SD Fargo, ND Bismarck, ND Bemidji, MN
	ML28897/PRO 02 – Solid Tumor My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response To One of These Agents	<ul style="list-style-type: none"> • 18 years or older • Advanced Solid tumors • Progressed following administration of standard of care treatment • Targeted therapy is considered the best available treatment option • Measurable disease • Otherwise healthy 	Sioux Falls, SD